Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Study Purpose
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years - 79 Years |
| Gender | All |
Inclusion Criteria:
- - Patient must be between 18 and 79 years of age.
- - Patient must have locoregionally recurrent or second primary HNSCC (oral cavity, oropharynx, larynx, hypopharynx) in a previously radiated field.
- - Patient must have undergone surgery with gross total resection and must be randomized within 8 weeks of surgery.
- - Patients must have high risk disease defined as: - Positive margins and/or extra nodal extension (ENE) - Positive margins are defined as malignancy at or within 1 mm of the margin.
- - ENE may be either gross or microscopic.
- - Patient must have a PD-L1 Combined Positive Score (CPS) >= 1 in a Clinical Laboratory Improvement Act (CLIA) certified laboratory.
- - Patient must have had prior radiation to the area of recurrent or second primary tumor.
- - Patient must have completed prior radiation a minimum of 6 months prior to randomization.
- - Patient must not have any evidence of distant disease based on baseline imaging done within 28 days prior to randomization.
- - Patient must not have received anti-PD-1/PD-L1 therapy for recurrent disease.
- - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- - Patient must have the ability to understand and the willingness to sign a written informed consent document.
- - Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- - Patient must not expect to conceive or father children by using by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment.
- - Absolute neutrophil count (ANC) >= 1,500/mcL (obtained =< 28 days prior to protocol randomization) - Platelets >= 100,000/mcL (obtained =< 28 days prior to protocol randomization) - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to protocol randomization) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional ULN (obtained =< 28 days prior to protocol randomization) - Creatinine clearance > 30 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to protocol randomization) - Patient must not have a current active infection that requires systemic treatment at time of randomization.
- - Patient must not have a history of non-infectious pneumonitis requiring steroids within 3 years prior to randomization.
- - Patient must not have a history of solid organ transplant or stem cell transplant.
- - Patient must not be on immunosuppressive medication within 7 days prior to randomization, EXCEPT for the following: a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b) systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c) steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification.
- - Patient must not have received a live vaccine within 30 days prior to the first dose of study drug.
- - Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients.
- - Patient must not have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- - Patient must not have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
- - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial as long as they have not been HIV-infected with a history of Kaposi sarcoma and/or multicentric Castleman disease.
- - Patient must not have a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT04671667 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Dan P Zandberg |
| Principal Investigator Affiliation | ECOG-ACRIN Cancer Research Group |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH |
| Overall Status | Recruiting |
| Countries | United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma |
PRIMARY OBJECTIVE:
- I. To evaluate overall survival (OS) of adjuvant pembrolizumab for 12 months compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk head and neck squamous cell carcinoma (HNSCC) patients.
- I. To evaluate the following endpoints in both arms: disease free survival (DFS), locoregional control, rates of distant metastasis, toxicity.
- II. To evaluate whether high PD-L1 expression (defined as Combined Positive Score [CPS] >= 20) is predictive of increased efficacy in the experimental group compared to control.
Arms
Active Comparator: Arm B (cisplatin, carboplatin, IMRT, PBRT)
Patients receive cisplatin or carboplatin IV on day 1. Treatment repeats every 7 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo IMRT or PBRT QD for a total of 30 fractions in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial.
Experimental: Arm C (pembrolizumab)
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial.
Interventions
Drug: - Carboplatin
Given IV
Drug: - Cisplatin
Given IV
Procedure: - Computed Tomography
Undergo CT
Radiation: - Intensity-Modulated Radiation Therapy
Undergo IMRT
Procedure: - Magnetic Resonance Imaging
Undergo MRI
Biological: - Pembrolizumab
Given IV
Radiation: - Proton Beam Radiation Therapy
Undergo PBRT
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Suspended
Address
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Status
Recruiting
Address
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Status
Recruiting
Address
Kaiser Permanente-Anaheim
Anaheim, California, 92806
Status
Recruiting
Address
Kaiser Permanente-Bellflower
Bellflower, California, 90706
Status
Recruiting
Address
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Status
Recruiting
Address
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Status
Recruiting
Address
Kaiser Permanente-Ontario
Ontario, California, 91761
Status
Active, not recruiting
Address
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, 95661
Status
Active, not recruiting
Address
Sutter Roseville Medical Center
Roseville, California, 95661
Status
Recruiting
Address
California Protons Cancer Therapy Center
San Diego, California, 92121
Status
Recruiting
Address
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510
Status
Recruiting
Address
Yale University
New Haven, Connecticut, 06520
Status
Recruiting
Address
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut, 06611
Status
Recruiting
Address
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut, 06385
Status
Recruiting
Address
MedStar Washington Hospital Center
Washington, District of Columbia, 20010
Status
Recruiting
Address
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
Status
Recruiting
Address
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Status
Active, not recruiting
Address
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
Status
Active, not recruiting
Address
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Status
Recruiting
Address
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324
Status
Suspended
Address
Moffitt Cancer Center-International Plaza
Tampa, Florida, 33607
Status
Recruiting
Address
Moffitt Cancer Center - McKinley Campus
Tampa, Florida, 33612
Status
Recruiting
Address
Moffitt Cancer Center
Tampa, Florida, 33612
Status
Recruiting
Address
Emory Proton Therapy Center
Atlanta, Georgia, 30308
Status
Recruiting
Address
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Status
Suspended
Address
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Status
Suspended
Address
Memorial Health University Medical Center
Savannah, Georgia, 31404
Status
Recruiting
Address
Northwestern University
Chicago, Illinois, 60611
Status
Recruiting
Address
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Status
Recruiting
Address
University of Illinois
Chicago, Illinois, 60612
Status
Recruiting
Address
Carle at The Riverfront
Danville, Illinois, 61832
Status
Suspended
Address
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Status
Recruiting
Address
Decatur Memorial Hospital
Decatur, Illinois, 62526
Status
Recruiting
Address
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Status
Recruiting
Address
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Status
Recruiting
Address
Crossroads Cancer Center
Effingham, Illinois, 62401
Status
Recruiting
Address
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Status
Active, not recruiting
Address
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
Status
Recruiting
Address
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Status
Recruiting
Address
Loyola University Medical Center
Maywood, Illinois, 60153
Status
Recruiting
Address
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois, 62269
Status
Recruiting
Address
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Status
Recruiting
Address
Springfield Clinic
Springfield, Illinois, 62702
Status
Recruiting
Address
Springfield Memorial Hospital
Springfield, Illinois, 62781
Status
Recruiting
Address
Carle Cancer Center
Urbana, Illinois, 61801
Status
Suspended
Address
The Carle Foundation Hospital
Urbana, Illinois, 61801
Status
Recruiting
Address
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
Status
Recruiting
Address
Reid Health
Richmond, Indiana, 47374
Status
Recruiting
Address
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa, 50023
Status
Recruiting
Address
Heartland Oncology and Hematology LLP
Council Bluffs, Iowa, 51503
Status
Recruiting
Address
Methodist Jennie Edmundson Hospital
Council Bluffs, Iowa, 51503
Status
Recruiting
Address
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Status
Recruiting
Address
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, 50309
Status
Recruiting
Address
Broadlawns Medical Center
Des Moines, Iowa, 50314
Status
Suspended
Address
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Status
Recruiting
Address
UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, Iowa, 50263
Status
Suspended
Address
Methodist West Hospital
West Des Moines, Iowa, 50266-7700
Status
Active, not recruiting
Address
University of Kansas Cancer Center
Kansas City, Kansas, 66160
Status
Active, not recruiting
Address
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210
Status
Active, not recruiting
Address
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, 66211
Status
Active, not recruiting
Address
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205
Status
Recruiting
Address
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Status
Recruiting
Address
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
Status
Recruiting
Address
UofL Health Medical Center Northeast
Louisville, Kentucky, 40245
Status
Suspended
Address
Maryland Proton Treatment Center
Baltimore, Maryland, 21201
Status
Recruiting
Address
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Status
Recruiting
Address
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, 21044
Status
Recruiting
Address
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061
Status
Recruiting
Address
Tufts Medical Center
Boston, Massachusetts, 02111
Status
Recruiting
Address
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Status
Active, not recruiting
Address
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Status
Active, not recruiting
Address
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334
Status
Recruiting
Address
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Status
Recruiting
Address
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Status
Suspended
Address
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Status
Active, not recruiting
Address
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
Status
Active, not recruiting
Address
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Status
Active, not recruiting
Address
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Status
Active, not recruiting
Address
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116
Status
Active, not recruiting
Address
Washington University School of Medicine
Saint Louis, Missouri, 63110
Status
Recruiting
Address
Mercy Hospital South
Saint Louis, Missouri, 63128
Status
Active, not recruiting
Address
Siteman Cancer Center-South County
Saint Louis, Missouri, 63129
Status
Active, not recruiting
Address
Siteman Cancer Center at Christian Hospital
Saint Louis, Missouri, 63136
Status
Recruiting
Address
Mercy Hospital Saint Louis
Saint Louis, Missouri, 63141
Status
Active, not recruiting
Address
Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri, 63376
Status
Suspended
Address
Mercy Hospital Springfield
Springfield, Missouri, 65804
Status
Recruiting
Address
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Status
Recruiting
Address
Logan Health Medical Center
Kalispell, Montana, 59901
Status
Recruiting
Address
Community Medical Center
Missoula, Montana, 59804
Status
Recruiting
Address
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
Omaha, Nebraska, 68114
Status
Recruiting
Address
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Status
Recruiting
Address
Oncology Associates PC
Omaha, Nebraska, 68114
Status
Recruiting
Address
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Status
Recruiting
Address
Montefiore Medical Center-Einstein Campus
Bronx, New York, 10461
Status
Recruiting
Address
Montefiore Medical Center - Moses Campus
Bronx, New York, 10467
Status
Recruiting
Address
Mount Sinai Union Square
New York, New York, 10003
Status
Recruiting
Address
Mount Sinai Chelsea
New York, New York, 10011
Status
Recruiting
Address
Mount Sinai Hospital
New York, New York, 10029
Status
Recruiting
Address
Stony Brook University Medical Center
Stony Brook, New York, 11794
Status
Suspended
Address
Randolph Hospital
Asheboro, North Carolina, 27203
Status
Recruiting
Address
Cone Health Cancer Center
Greensboro, North Carolina, 27403
Status
Recruiting
Address
Annie Penn Memorial Hospital
Reidsville, North Carolina, 27320
Status
Recruiting
Address
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Status
Recruiting
Address
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Status
Recruiting
Address
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
Status
Recruiting
Address
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Status
Recruiting
Address
Miami Valley Hospital South
Centerville, Ohio, 45459
Status
Recruiting
Address
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Status
Recruiting
Address
Premier Blood and Cancer Center
Dayton, Ohio, 45409
Status
Recruiting
Address
Dayton Physician LLC - Englewood
Dayton, Ohio, 45415
Status
Recruiting
Address
Miami Valley Hospital North
Dayton, Ohio, 45415
Status
Recruiting
Address
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Status
Recruiting
Address
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Status
Recruiting
Address
Miami Valley Cancer Care and Infusion
Greenville, Ohio, 45331
Status
Recruiting
Address
Greater Dayton Cancer Center
Kettering, Ohio, 45409
Status
Recruiting
Address
Kettering Medical Center
Kettering, Ohio, 45429
Status
Recruiting
Address
Upper Valley Medical Center
Troy, Ohio, 45373
Status
Recruiting
Address
Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, 73505
Status
Recruiting
Address
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Status
Suspended
Address
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Status
Suspended
Address
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, 97015
Status
Recruiting
Address
Providence Newberg Medical Center
Newberg, Oregon, 97132
Status
Recruiting
Address
Providence Portland Medical Center
Portland, Oregon, 97213
Status
Recruiting
Address
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Status
Recruiting
Address
UPMC Altoona
Altoona, Pennsylvania, 16601
Status
Recruiting
Address
Geisinger Medical Center
Danville, Pennsylvania, 17822
Status
Recruiting
Address
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
Status
Recruiting
Address
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Status
Recruiting
Address
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Status
Recruiting
Address
Jefferson Torresdale Hospital
Philadelphia, Pennsylvania, 19114
Status
Active, not recruiting
Address
Temple University Hospital
Philadelphia, Pennsylvania, 19140
Status
Recruiting
Address
UPMC-Saint Margaret
Pittsburgh, Pennsylvania, 15215
Status
Recruiting
Address
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232
Status
Active, not recruiting
Address
UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania, 15232
Status
Recruiting
Address
UPMC-Passavant Hospital
Pittsburgh, Pennsylvania, 15237
Status
Recruiting
Address
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
Status
Recruiting
Address
UPMC Memorial
York, Pennsylvania, 17408
Status
Recruiting
Address
Medical University of South Carolina
Charleston, South Carolina, 29425
Status
Recruiting
Address
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Status
Recruiting
Address
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Status
Recruiting
Address
Avera Cancer Institute at Yankton
Yankton, South Dakota, 57078
Status
Recruiting
Address
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232
Status
Active, not recruiting
Address
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Status
Recruiting
Address
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235
Status
Recruiting
Address
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Status
Recruiting
Address
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
Status
Suspended
Address
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Status
Recruiting
Address
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Status
Recruiting
Address
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Status
Recruiting
Address
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
Status
Recruiting
Address
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Status
Recruiting
Address
Drexel Town Square Health Center
Oak Creek, Wisconsin, 53154
Status
Recruiting
Address
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235-1495
Status
Recruiting
Address
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, Wisconsin, 53095
